From the Edward A. Doisy Department of Biochemistry and Molecular Biology, Saint Louis University, St. Louis, Missouri 63103.
the Department of Neurology, Washington University School of Medicine, St. Louis, Missouri 63110, and.
J Biol Chem. 2019 Apr 26;294(17):6696-6709. doi: 10.1074/jbc.RA118.005889. Epub 2019 Mar 1.
Aggregates of the RNA-binding protein TDP-43 (TAR DNA-binding protein) are a hallmark of the overlapping neurodegenerative disorders amyotrophic lateral sclerosis (ALS) and frontotemporal dementia. The process of TDP-43 aggregation remains poorly understood, and whether it includes formation of intermediate complexes is unknown. Here, we analyzed aggregates derived from purified TDP-43 under semidenaturing conditions, identifying distinct oligomeric complexes at the initial time points before the formation of large aggregates. We found that this early oligomerization stage is primarily driven by TDP-43's RNA-binding region. Specific binding to GU-rich RNA strongly inhibited both TDP-43 oligomerization and aggregation, suggesting that RNA interactions are critical for maintaining TDP-43 solubility. Moreover, we analyzed TDP-43 liquid-liquid phase separation and detected similar detergent-resistant oligomers upon maturation of liquid droplets into solid-like fibrils. These results strongly suggest that the oligomers form during the early steps of TDP-43 misfolding. Importantly, the ALS-linked TDP-43 mutations A315T and M337V significantly accelerate aggregation, rapidly decreasing the monomeric population and shortening the oligomeric phase. We also show that aggregates generated from purified TDP-43 seed intracellular aggregation detected by established TDP-43 pathology markers. Remarkably, cytoplasmic aggregate seeding was detected earlier for the A315T and M337V variants and was 50% more widespread than for WT TDP-43 aggregates. We provide evidence for an initial step of TDP-43 self-assembly into intermediate oligomeric complexes, whereby these complexes may provide a scaffold for aggregation. This process is altered by ALS-linked mutations, underscoring the role of perturbations in TDP-43 homeostasis in protein aggregation and ALS-FTD pathogenesis.
TDP-43(TAR DNA 结合蛋白)RNA 结合蛋白的聚集体是肌萎缩性侧索硬化症(ALS)和额颞叶痴呆等重叠神经退行性疾病的标志。TDP-43 聚集的过程仍然知之甚少,并且是否包括中间复合物的形成尚不清楚。在这里,我们在半变性条件下分析了从纯化的 TDP-43 中衍生的聚集体,在形成大聚集体之前的初始时间点鉴定出不同的寡聚复合物。我们发现,这个早期寡聚化阶段主要是由 TDP-43 的 RNA 结合区域驱动的。与富含 GU 的 RNA 的特异性结合强烈抑制 TDP-43 的寡聚化和聚集,表明 RNA 相互作用对于维持 TDP-43 的可溶性至关重要。此外,我们分析了 TDP-43 的液-液相分离,并在液滴成熟为固态纤维时检测到类似的去污剂抗性寡聚物。这些结果强烈表明,寡聚物是在 TDP-43 错误折叠的早期步骤中形成的。重要的是,与 ALS 相关的 TDP-43 突变 A315T 和 M337V 显著加速聚集,迅速减少单体种群并缩短寡聚相。我们还表明,从纯化的 TDP-43 中产生的聚集体作为建立的 TDP-43 病理学标志物检测到细胞内聚集的种子。值得注意的是,A315T 和 M337V 变体的细胞质聚集体种子更早被检测到,比 WT TDP-43 聚集体更广泛 50%。我们提供了 TDP-43 自我组装成中间寡聚复合物的初始步骤的证据,其中这些复合物可能为聚集提供支架。这一过程被 ALS 相关突变改变,突出了 TDP-43 动态平衡中扰动在蛋白聚集和 ALS-FTD 发病机制中的作用。